CE

Cellbion Co., Ltd

Develops radiopharmaceuticals and radioligand therapies for oncology.

308430 | KO

Overview

Corporate Details

ISIN(s):
KR7308430008
LEI:
Country:
South Korea
Address:
서울특별시 종로구 대학로 103 서울대학교 암연구소 6층, 종로구

Description

Cellbion Co., Ltd. is a company engaged in the research, development, and commercialization of radiopharmaceuticals. It specializes in Radioligand Therapy (RLT), developing both therapeutic and diagnostic agents to address unmet medical needs, primarily in oncology. The company's pipeline features innovative treatments, including antibody-based approaches and radioactive probes for medical imaging. A key therapeutic candidate in its portfolio is Lu-177-DGUL. Cellbion's focus is on advancing the field of nuclear medicine through novel drug development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-01-31 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean HTML 11.5 KB
2024-12-12 00:00
주주명부폐쇄기간또는기준일설정
Korean HTML 4.1 KB
2024-11-13 00:00
분기보고서 (2024.09)
Korean HTML 988.0 KB
2024-11-11 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 22.9 KB
2024-10-23 00:00
주식등의대량보유상황보고서(약식)
Korean HTML 74.1 KB
2024-10-22 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 21.7 KB
2024-10-22 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 22.5 KB
2024-10-22 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 21.7 KB
2024-10-22 00:00
주식등의대량보유상황보고서(일반)
Korean HTML 101.9 KB
2024-10-22 00:00
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 23.5 KB
2024-10-11 00:00
증권발행실적보고서
Korean HTML 166.9 KB
2024-10-07 00:00
[기재정정]투자설명서
Korean HTML 3.2 MB
2024-10-04 00:00
[발행조건확정]증권신고서(지분증권)
Korean HTML 390.9 KB
2024-10-04 00:00
[기재정정]투자설명서
Korean HTML 3.2 MB
2024-09-30 00:00
투자설명서
Korean HTML 2.8 MB

Automate Your Workflow. Get a real-time feed of all Cellbion Co., Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellbion Co., Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cellbion Co., Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.